The diverse roles of IRF4 in late germinal center B-cell differentiation

Immunological Reviews

Volumn 247, Issue 1, 2012, Pages 73-92

  De Silva, Nilushi S ^a   Simonetti, Giorgia ^a   Heise, Nicole ^a   Klein, Ulf ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

B cells; Cancer; Differentiation; IRF4; Transcription factors

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; B LYMPHOCYTE RECEPTOR; CD40 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN 6; INTERLEUKIN 7; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MYC PROTEIN; PROTEIN BCL 6; STAT3 PROTEIN; TRANSCRIPTION FACTOR PAX5; X BOX BINDING PROTEIN 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; DENDRITIC CELL; EXTRACELLULAR SPACE; GENE LOCUS; GENE REARRANGEMENT; GERMINAL CENTER; HODGKIN DISEASE; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; MACROPHAGE; MEMORY CELL; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENOMEGALY;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; GERMINAL CENTER; HUMANS; INTERFERON REGULATORY FACTORS; MODELS, BIOLOGICAL;

EID: 84859713325     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2012.01113.x     Document Type: Article

References (136)

1. Pongubala JM, Nagulapalli S, Klemsz MJ, McKercher SR, Maki RA, Atchison ML. PU.1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3′ enhancer activity. Mol Cell Biol 1992;12:368-378.
2. Brass AL, Kehrli E, Eisenbeis CF, Storb U, Singh H. Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1. Genes Dev 1996;10:2335-2347.
3. Eisenbeis CF, Singh H, Storb U. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev 1995;9:1377-1387.
4. Matsuyama T, et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res 1995;23:2127-2136.
5. Yamagata T, et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol Cell Biol 1996;16:1283-1294.
6. Iida S, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997;17:226-230.
7. Mittrucker HW, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997;275:540-543.
8. Falini B, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084-2092.
9. Cattoretti G, Shaknovich R, Smith PM, JÃck H-M, Murty VV, Alobeid B. Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol 2006;177:6930-6939.
10. Angelin-Duclos C, et al. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol 2000;165:5462-5471.
11. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005;5:230-242.
12. Klein U, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006;7:773-782.
13. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006;25:225-236.
14. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008;8:22-33.
15. Shaffer AL, et al. IRF4 addiction in multiple myeloma. Nature 2008;454:226-231.
16. Acquaviva J, Chen X, Ren R. IRF-4 functions as a tumor suppressor in early B-cell development. Blood 2008;112:3798-3806.
17. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008;26:535-584.
18. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: immunity. Malignancy! Therapy? Clin Cancer Res 2009;15:2954-2961.
19. Brass AL, Zhu AQ, Singh H. Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers. EMBO J 1999;18:977-991.
20. Nagulapalli S, Atchison ML. Transcription factor Pip can enhance DNA binding by E47, leading to transcriptional synergy involving multiple protein domains. Mol Cell Biol 1998;18:4639-4650.
21. Meraro D, et al. Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors. J Immunol 1999;163:6468-6478.
22. Sharf R, et al. Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. J Biol Chem 1997;272:9785-9792.
23. Ortiz MA, Light J, Maki RA, Assa-Munt N. Mutation analysis of the Pip interaction domain reveals critical residues for protein-protein interactions. Proc Natl Acad Sci USA 1999;96:2740-2745.
24. Zheng Y, et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 2009;458:351-356.
25. Lohoff M, et al. Dysregulated T helper cell differentiation in the absence of interferon regulatory factor 4. Proc Natl Acad Sci USA 2002;99:11808-11812.
26. Brustle A, et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007;8:958-966.
27. Honma K, et al. Interferon regulatory factor 4 negatively regulates the production of proinflammatory cytokines by macrophages in response to LPS. Proc Natl Acad Sci USA 2005;102:16001-16006.
28. Negishi H, et al. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci USA 2005;102:15989-15994.
29. Suzuki S, et al. Critical roles of interferon regulatory factor 4 in CD11bhighCD8alpha-dendritic cell development. Proc Natl Acad Sci USA 2004;101:8981-8986.
30. Eguchi J, et al. Transcriptional control of adipose lipid handling by IRF4. Cell Metab 2011;13:249-259.
31. Lu R, Medina KL, Lancki DW, Singh H. IRF-4, 8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes Dev 2003;17:1703-1708.
32. Ma S, Pathak S, Trinh L, Lu R. Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development. Blood 2008;111:1396-1403.
33. Kim J, et al. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity 1999;10:345-355.
34. Thompson EC, et al. Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity 2007;26:335-344.
35. Gomez-del Arco P, Maki K, Georgopoulos K. Phosphorylation controls Ikaros's ability to negatively regulate the G(1)-S transition. Mol Cell Biol 2004;24:2797-2807.
36. Wang JH, et al. Aiolos regulates B cell activation and maturation to effector state. Immunity 1998;9:543-553.
37. Ma S, Pathak S, Mandal M, Trinh L, Clark MR, Lu R. Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol 2010;30:4149-4158.
38. Johnson K, et al. Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling. Immunity 2008;28:335-345.
39. Perkel JM, Atchison ML. A two-step mechanism for recruitment of Pip by PU.1. J Immunol 1998;160:241-252.
40. Schweitzer BL, DeKoter RP. Analysis of gene expression and Ig transcription in PU.1/Spi-B-deficient progenitor B cell lines. J Immunol 2004;172:144-154.
41. Lazorchak AS, Schlissel MS, Zhuang Y. E2A and IRF-4/Pip promote chromatin modification and transcription of the immunoglobulin kappa locus in pre-B cells. Mol Cell Biol 2006;26:810-821.
42. Inlay MA, Tian H, Lin T, Xu Y. Important roles for E protein binding sites within the immunoglobulin kappa chain intronic enhancer in activating Vkappa Jkappa rearrangement. J Exp Med 2004;200:1205-1211.
43. Pathak S, Ma S, Trinh L, Lu R. A role for interferon regulatory factor 4 in receptor editing. Mol Cell Biol 2008;28:2815-2824.
44. Retter MW, Nemazee D. Receptor editing occurs frequently during normal B cell development. J Exp Med 1998;188:1231-1238.
45. Sciammas R, Li Y, Warmflash A, Song Y, Dinner AR, Singh H. An incoherent regulatory network architecture that orchestrates B cell diversification in response to antigen signaling. Mol Syst Biol 2011;7:495.
46. Lin L, Gerth AJ, Peng SL. Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor. J Exp Med 2004;200:115-122.
47. Cattoretti G, et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995;86:45-53.
48. Allman D, et al. BCL-6 expression during B-cell activation. Blood 1996;87:5257-5268.
49. Ranucolo SM. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 2007;8:705-714.
50. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000;13:199-212.
51. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004;173:1158-1165.
52. Vasanwala FH, Kusam S, Toney LM, Dent AL. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol 2002;169:1922-1929.
53. Shaffer AL, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002;17:51-62.
54. Niu H. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev 1998;12:1953-1961.
55. Berescchenko OR, et al. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002;32:606-613.
56. Basso K, et al. Tracking CD40 signaling during germinal center development. Blood 2004;104:4088-4096.
57. Saito M, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007;12:280-292.
58. Shaffer AL, et al. Signatures of the immune response. Immunity 2001;15:375-385.
59. Grumont RJ, Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes. J Exp Med 2000;191:1281-1292.
60. Kuo TC, Shaffer AL, Haddad J, Choi YS, Staudt LM, Calame K. Repression of BCL-6 is required for the formation of human memory B cells in vitro. J Exp Med 2007;204:819-830.
61. Cattoretti G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005;7:445-455.
62. Gupta S, Jiang M, Anthony A, Pernis AB. Lineage-specific modulation of interleukin 4 signaling by interferon regulatory factor 4. J Exp Med 1999;190:1837-1848.
63. Gonda H, et al. The balance between Pax5 and Id2 activities is the key to AID gene expression. J Exp Med 2003;198:1427-1437.
64. Nera K-P, et al. Loss of Pax5 promotes plasma cell differentiation. Immunity 2006;24:283-293.
65. Sayegh C, et al. E-proteins directly regulate expression of activation-induced deaminase in mature B cells. Nat Immunol 2003;4:585-593.
66. Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 1994;77:297-306.
67. Shapiro-Shelef M, Lin K-I, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 2003;19:607-620.
68. Kallies A, et al. Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity 2007;26:555-566.
69. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999;401:556-562.
70. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity 2007;27:49-63.
71. Reimold AM, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300-307.
72. Shaffer AL, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004;21:81-93.
73. Holodick NE, Tumang JR, Rothstein TL. Immunoglobulin secretion by B1 cells: differential intensity and IRF4-dependence of spontaneous IgM secretion by peritoneal and splenic B1 cells. Eur J Immunol 2010;40:3007-3016.
74. Tumang JR, et al. Cutting edge: spontaneously Ig-secreting B-1 cells violate the accepted paradigm for expression of differentiation-associated transcription factors. J Immunol 2005;174:3173-3177.
75. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 2006;24:269-281.
76. Lin K-I, Angelin-Duclos C, Kuo TC, Calame K. Blimp-1-dependent repression of Pax-5 Is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol 2002;22:4771-4780.
77. Sciammas R, David M. Modular nature of Blimp-1 in the regulation of gene expression during B cell maturation. J Immunol 2004;172:5427-5440.
78. Decker T, et al. Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis. Immunity 2009;30:508-520.
79. Nutt SL, Taubenheim N, Hasbold J, Corcoran LM, Hodgkin PD. The genetic network controlling plasma cell differentiation. Semin Immunol 2011;23:341-349.
80. Eisenbeis CF, Singh H, Storb U. PU.1 is a component of a multiprotein complex which binds an essential site in the murine immunoglobulin lambda 2-4 enhancer. Mol Cell Biol 1993;13:6452-6461.
81. Kallies A, et al. Plasma cell ontogeny defined by quantitative changes in Blimp-1 expression. J Exp Med 2004;200:967-977.
82. Muto A, et al. Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switch. EMBO J 2010;29:4048-4061.
83. Muto A, et al. Identification of Bach2 as a B-cell-specific partner for small Maf proteins that negatively regulate the immunoglobulin heavy chain gene 3[prime] enhancer. EMBO J 1998;17:5734-5743.
84. Ochiai K, et al. Plasmacytic transcription factor Blimp-1 Is repressed by Bach2 in B cells. J Biol Chem 2006;281:38226-38234.
85. Ochiai K, Muto A, Tanaka H, Takahashi S, Igarashi K. Regulation of the plasma cell transcription factor Blimp-1 gene by Bach2 and Bcl6. Int Immunol 2008;20:453-460.
86. Chopin M, Chacon-Martinez CA, Jessberger R. Fine tuning of IRF-4 expression by SWAP-70 controls the initiation of plasma cell development. Eur J Immunol 2011;41:3063-3074.
87. Morgan MAJ, et al. Blimp-1/Prdm1 alternative promoter usage during mouse development and plasma cell differentiation. Mol Cell Biol 2009;29:5813-5827.
88. Ozaki K, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 2004;173:5361-5371.
89. Kwon H, et al. Analysis of interleukin-21-induced prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 2009;31:941-952.
90. Ettinger R, et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005;175:7867-7879.
91. Diehl SA, et al. STAT3-mediated up-regulation of BLIMP1 is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J Immunol 2008;180:4805-4815.
92. Reljic R, Wagner SD, Peakman LJ, Fearon DT. Suppression of signal transducer and activator of transcription 3â€"dependent B lymphocyte terminal differentiation by Bcl-6. J Exp Med 2000;192:1841-1848.
93. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-563.
94. Lee C, et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J Exp Med 2006;203:63-72.
95. Feng J, Wang H, Shin DM, Masiuk M, Qi CF, Morse HC 3rd. IFN regulatory factor 8 restricts the size of the marginal zone and follicular B cell pools. J Immunol 2011;186:1458-1466.
96. Klein U, et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA 2003;100:2639-2644.
97. Casola S, et al. Tracking germinal center B cells expressing germ-line immunoglobulin gamma1 transcripts by conditional gene targeting. Proc Natl Acad Sci USA 2006;103:7396-7401.
98. Jourdan M, et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 2009;114:5173-5181.
99. Salaverria I, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 2011;118:139-147.
100. Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
101. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006;107:4090-4100.
102. Pasqualucci L, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006;203:311-317.
103. Mandelbaum J, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010;18:568-579.
104. Lenz G, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 2007;204:633-643.
105. Lenz G, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520-13525.
106. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.
107. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:1812-1826.
108. Tsuboi K, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000;14:449-456.
109. Aldinucci D, et al. IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. Br J Haematol 2010;148:115-118.
110. Li S, et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011;117:5157-5165.
111. Lopez-Girona A, et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011;154:325-336.
112. Klein F, et al. Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. J Immunol 2005;174:367-375.
113. Jo SH, Schatz JH, Acquaviva J, Singh H, Ren R. Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. Blood 2010;116:2759-2767.
114. Pathak S, et al. IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS ONE 2011;6:e22628.
115. Di Bernardo MC, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 2008;40:1204-1210.
116. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003;21:841-894.
117. Crowther-Swanepoel D, et al. Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. Hum Mol Genet 2010;19:1840-1845.
118. Crowther-Swanepoel D, et al. Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk. Br J Haematol 2010;150:473-479.
119. Gaboli M, et al. Mzf1 controls cell proliferation and tumorigenesis. Genes Dev 2001;15:1625-1630.
120. Crowther-Swanepoel D, et al. Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. Blood 2010;116:5957-5960.
121. Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 2010;24:512-520.
122. Chang CC, et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002;100:4671-4675.
123. Havelange V, et al. IRF4 mutations in chronic lymphocytic leukemia. Blood 2011;118:2827-2829.
124. Klemsz MJ, McKercher SR, Celada A, Van Beveren C, Maki RA. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 1990;61:113-124.
125. Rao S, Matsumura A, Yoon J, Simon MC. SPI-B activates transcription via a unique proline, serine, and threonine domain and exhibits DNA binding affinity differences from PU.1. J Biol Chem 1999;274:11115-11124.
126. Pongubala JM, et al. Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. Science 1993;259:1622-1625.
127. Himmelmann A, Riva A, Wilson GL, Lucas BP, Thevenin C, Kehrl JH. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 1997;90:3984-3995.
128. van der Stoep N, Quinten E, Marcondes Rezende M, van den Elsen PJ. E47, IRF-4, and PU.1 synergize to induce B-cell-specific activation of the class II transactivator promoter III (CIITA-PIII). Blood 2004;104:2849-2857.
129. Su GH, Ip HS, Cobb BS, Lu MM, Chen HM, Simon MC. The Ets protein Spi-B is expressed exclusively in B cells and T cells during development. J Exp Med 1996;184:203-214.
130. Rosenbauer F, Waring JF, Foerster J, Wietstruk M, Philipp D, Horak I. Interferon consensus sequence binding protein and interferon regulatory factor-4/Pip form a complex that represses the expression of the interferon-stimulated gene-15 in macrophages. Blood 1999;94:4274-4281.
131. Meraro D, Gleit-Kielmanowicz M, Hauser H, Levi BZ. IFN-stimulated gene 15 is synergistically activated through interactions between the myelocyte/lymphocyte-specific transcription factors, PU.1, IFN regulatory factor-8/IFN consensus sequence binding protein, and IFN regulatory factor-4: characterization of a new subtype of IFN-stimulated response element. J Immunol 2002;168:6224-6231.
132. Rengarajan J, Mowen KA, McBride KD, Smith ED, Singh H, Glimcher LH. Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med 2002;195:1003-1012.
133. Hu CM, Jang SY, Fanzo JC, Pernis AB. Modulation of T cell cytokine production by interferon regulatory factor-4. J Biol Chem 2002;277:49238-49246.
134. Gupta S, Anthony A, Pernis AB. Stage-specific modulation of IFN-regulatory factor 4 function by Kruppel-type zinc finger proteins. J Immunol 2001;166:6104-6111.
135. Gupta S, et al. Molecular cloning of IBP, a SWAP-70 homologous GEF, which is highly expressed in the immune system. Hum Immunol 2003;64:389-401.
136. Chen Q, et al. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 2008;29:899-911.